(VIANEWS) – Viad Corp (VVI), Clearwater Paper Corporation (CLW), Amgen (AMGN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Viad Corp (VVI)
25.3% sales growth and 8.6% return on equity
Viad Corp operates as an experiential leisure travel, and live events and marketing services company in the United States, Canada, the United Kingdom, the United Arab Emirates, Netherlands, and Iceland. It operates through Pursuit, Spiro, and GES Exhibitions segments. The Pursuit segment offers vertically integrated attractions and hospitality in destinations with a collection of attractions, lodges, and sightseeing tours. The GES Exhibition operates as an exhibition services company that partners with exhibition and conference organizers as a full-service provider of strategic and logistics solutions to manage the complexity of their shows. The Spiro operates experiential marketing agency that partners with brands around the world to manage and elevate their global experiential marketing activities. In addition, the company offers a collection of travel experiences in recreational attractions, food and beverage, retail, and ground transportation services. It serves event organizers and corporate brand marketers directly, as well as through a distribution channel network that include tour operators, tour wholesalers, destination management companies, and retail travel agencies. Viad Corp was founded in 1926 and is headquartered in Scottsdale, Arizona.
Earnings Per Share
As for profitability, Viad Corp has a trailing twelve months EPS of $0.15.
PE Ratio
Viad Corp has a trailing twelve months price to earnings ratio of 229.93. Meaning, the purchaser of the share is investing $229.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.6%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 127.8% and 66.4%, respectively.
Moving Average
Viad Corp’s worth is under its 50-day moving average of $34.97 and higher than its 200-day moving average of $32.69.
2. Clearwater Paper Corporation (CLW)
22.7% sales growth and 15.84% return on equity
Clearwater Paper Corporation produces and sells private label tissue and bleached paperboard products in the United States and internationally. The company operates through two segments, Consumer Products, and Pulp and Paperboard. The Consumer Products segment manufactures and sells a line of at-home tissue products, including bath tissues, paper towels, facial tissues, and napkins; recycled fiber value grade products; and away-from-home products and parent rolls. This segment sells its products to retailers and wholesale distributors, including grocery, drug, mass merchants, and discount stores. The Pulp and Paperboard segment manufactures and markets bleached paperboard, folding cartons, liquid packaging, cups and plates, blister and carded packaging, top sheet and commercial printing grades and softwood pulp products, as well as offers custom sheeting, slitting and cutting of paperboard. It sells its products to packaging converters, folding carton converters, merchants, and commercial printers. Clearwater Paper Corporation was incorporated in 2005 and is headquartered in Spokane, Washington.
Earnings Per Share
As for profitability, Clearwater Paper Corporation has a trailing twelve months EPS of $5.92.
PE Ratio
Clearwater Paper Corporation has a trailing twelve months price to earnings ratio of 8.56. Meaning, the purchaser of the share is investing $8.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.84%.
Yearly Top and Bottom Value
Clearwater Paper Corporation’s stock is valued at $50.68 at 20:22 EST, below its 52-week high of $53.74 and way higher than its 52-week low of $29.22.
Volume
Today’s last reported volume for Clearwater Paper Corporation is 32294 which is 82.41% below its average volume of 183634.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.6%, now sitting on 2.05B for the twelve trailing months.
3. Amgen (AMGN)
22.2% sales growth and 72.57% return on equity
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Per Share
As for profitability, Amgen has a trailing twelve months EPS of $12.48.
PE Ratio
Amgen has a trailing twelve months price to earnings ratio of 21.42. Meaning, the purchaser of the share is investing $21.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 72.57%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 16, 2024, the estimated forward annual dividend rate is 9 and the estimated forward annual dividend yield is 2.88%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22%, now sitting on 29.53B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 0.6% and positive 4% for the next.
4. WD-40 Company (WDFC)
9.8% sales growth and 33.12% return on equity
WD-40 Company develops and sells maintenance products, and homecare and cleaning products in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company offers multi-purpose maintenance products, including aerosol sprays, non-aerosol trigger sprays, and in liquid-bulk form products under the WD-40 Multi-Use brand name for various consumer uses and industrial applications; and specialty maintenance products, such as penetrants, degreasers, corrosion inhibitors, greases, lubricants, and rust removers under the WD-40 Specialist brand, as well as various products under the WD-40 Bike brand name. It also provides multi-purpose and specialty drip oils, and spray lubricant products, as well as other specialty maintenance products under the 3-IN-ONE brand name; and professional spray maintenance products and lubricants for the bike market under the GT85 brand name. In addition, the company offers automatic toilet bowl cleaners under the 2000 Flushes brand name; aerosol and liquid trigger carpet stain and odor eliminators under the Spot Shot brand; room and rug deodorizers under the Carpet Fresh brand name; carpet and household cleaners, and rug and room deodorizers under the 1001 brand; heavy-duty hand cleaner products under the Lava brand name in the United States, as well as under the Solvol brand name in Australia; and liquid mildew stain removers and automatic toilet bowl cleaners under the X-14 brand name. It sells its products primarily through warehouse club stores, hardware stores, automotive parts outlets, industrial distributors and suppliers, mass retail and home center stores, value retailers, grocery stores, online retailers, farm supply, sport retailers, and independent bike dealers. WD-40 Company was founded in 1953 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, WD-40 Company has a trailing twelve months EPS of $5.03.
PE Ratio
WD-40 Company has a trailing twelve months price to earnings ratio of 43.96. Meaning, the purchaser of the share is investing $43.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.12%.
Yearly Top and Bottom Value
WD-40 Company’s stock is valued at $221.12 at 20:22 EST, way under its 52-week high of $278.78 and way higher than its 52-week low of $182.87.
Moving Average
WD-40 Company’s worth is below its 50-day moving average of $228.97 and under its 200-day moving average of $234.97.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jul 19, 2024, the estimated forward annual dividend rate is 3.52 and the estimated forward annual dividend yield is 1.59%.
